Condition: COPD · Hypercapnia · Exacerbation Copd · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
This multicenter, cross-over study aims to investigate the effects of two different respiratory strategies, the use of high flow nasal cannula (NHF) and the use of home mechanic ventilation (HMV), both associated with standard oxygen therapy, in patients with COPD and persistent hypercapnia following a severe acute exacerbation. The purpose is to evaluate whether the clinical benefits, in terms of reduction in PaCO2 levels, resulting from the use of NHF are non-inferior to those obtained from the use of HMV. Partecipants will be randomized at 1:1 ratio into two groups: group 1: will start the respiratory strategy under study (NHF + standard oxygen therapy) as first treatment group 2 will start the control respiratory strategy (HMV + standard oxygen therapy) as first treatment. The study has a crossover design: each patient will undergo treatment with the two different respiratory strategies, NHF and HMV, each lasting for 3 months
This description comes directly from the study's public registry record.
Lara Pisani, Prof.ssa · 0512143257 · lara.pisani@unibo.it
Always discuss trial participation with your own doctor first.
| Ospedale S Donato | Arezzo, Italy | Recruiting |
| Bolzano Hospital | Bolzano, Italy | Recruiting |
| Azienda Ospedaliera Universitaria Policlinico "G. Rodolico-Sn Marco" | Catania, Italy | Recruiting |
| ICS Maugeri Spa Società Benefit IRCCS | Pavia, Italy | Recruiting |
| Azienda Unità Sanitaria Locale | Piacenza, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07065799